This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Zoster sine herpete

Authoring team

Facial palsy secondary to herpes zoster virus has traditionally been associated with Ramsay Hunt syndrome (typical cutaneous vesicles and cochleovestibular dysfunction). However vesiculation may not necessarily appear (zoster sine herpete) or may be delayed in up to half of patients

  • preherpetic neuralgia (dermatomal pain and dysaesthesia before vesiculation) may be the only clinical indicator that herpes zoster virus is involved
  • almost a third of facial palsies previously diagnosed as idiopathic are thought to be due to zoster sine herpete

Treatment is with prednisolone and aciclovir (1)

  • 2000 mg/day of aciclovir seems to be effective in patients with zoster sine herpete
  • on the basis of current evidence, in the absence of major pain or evidence of vesicles, this dose (2000mg per day) would be adequate with steroids for treating Bell's palsy associated with herpes zoster virus

Reference:

  1. Holland NJ, Weiner GM. Recent developments in Bell's palsy.BMJ. 2004 Sep 4;329(7465):553-7

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.